XERIJECT

Serial Number 87450253
606

Registration Progress

Application Filed
May 15, 2017
Under Examination
Dec 5, 2017
Approved for Publication
Oct 10, 2017
Published for Opposition
Oct 10, 2017
Registered

Trademark Image

XERIJECT

Basic Information

Serial Number
87450253
Filing Date
May 15, 2017
Published for Opposition
October 10, 2017
Abandonment Date
January 11, 2021
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Jan 11, 2021
Classes
042

Rights Holder

Xeris Pharmaceuticals, Inc.

03
Address
180 N LaSalle Street, Suite 1810
Chicago, IL 60601

Ownership History

Xeris Pharmaceuticals, Inc.

Original Applicant
03
Austin, TX

Xeris Pharmaceuticals, Inc.

Owner at Publication
03
Chicago, IL

Legal Representation

Attorney
Tracy-Gene G. Durkin

USPTO Deadlines

All Deadlines Cleared

All 2 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

46 events
Date Code Type Description Documents
Jun 23, 2022 ASCK I ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY Loading...
May 19, 2022 ASCK I ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY Loading...
Jan 11, 2021 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Jan 11, 2021 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Jun 25, 2020 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jun 24, 2020 EX5G S SOU EXTENSION 5 GRANTED Loading...
Jun 23, 2020 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Jun 4, 2020 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jun 4, 2020 EXT5 S SOU EXTENSION 5 FILED Loading...
May 22, 2020 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
May 22, 2020 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
May 22, 2020 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
May 22, 2020 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
May 22, 2020 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Dec 5, 2019 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Dec 3, 2019 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Dec 3, 2019 EXT4 S SOU EXTENSION 4 FILED Loading...
Dec 3, 2019 EX4G S SOU EXTENSION 4 GRANTED Loading...
Jun 6, 2019 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jun 4, 2019 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jun 4, 2019 EXT3 S SOU EXTENSION 3 FILED Loading...
Jun 4, 2019 EX3G S SOU EXTENSION 3 GRANTED Loading...
Nov 2, 2018 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Oct 31, 2018 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Oct 31, 2018 EXT2 S SOU EXTENSION 2 FILED Loading...
Oct 31, 2018 EX2G S SOU EXTENSION 2 GRANTED Loading...
Jun 27, 2018 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Jun 27, 2018 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
May 31, 2018 DOCK D ASSIGNED TO EXAMINER Loading...
May 12, 2018 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
May 10, 2018 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
May 10, 2018 EXT1 S SOU EXTENSION 1 FILED Loading...
May 10, 2018 EX1G S SOU EXTENSION 1 GRANTED Loading...
Dec 5, 2017 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Oct 10, 2017 PUBO A PUBLISHED FOR OPPOSITION Loading...
Oct 10, 2017 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Sep 20, 2017 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Sep 5, 2017 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Aug 21, 2017 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Aug 21, 2017 GNEA F EXAMINERS AMENDMENT E-MAILED Loading...
Aug 21, 2017 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Aug 21, 2017 ALIE A ASSIGNED TO LIE Loading...
Aug 21, 2017 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Aug 14, 2017 DOCK D ASSIGNED TO EXAMINER Loading...
May 19, 2017 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
May 18, 2017 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 042
pharmaceutical research and development; pharmaceutical drug formulation and development services
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
042